JP2023552329A5 - - Google Patents
Info
- Publication number
- JP2023552329A5 JP2023552329A5 JP2023532489A JP2023532489A JP2023552329A5 JP 2023552329 A5 JP2023552329 A5 JP 2023552329A5 JP 2023532489 A JP2023532489 A JP 2023532489A JP 2023532489 A JP2023532489 A JP 2023532489A JP 2023552329 A5 JP2023552329 A5 JP 2023552329A5
- Authority
- JP
- Japan
- Prior art keywords
- suspension
- approximately
- dose
- paliperidone
- palmitate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025173295A JP2026027255A (ja) | 2020-11-30 | 2025-10-15 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119405P | 2020-11-30 | 2020-11-30 | |
| US63/119,405 | 2020-11-30 | ||
| PCT/EP2021/062147 WO2022111859A1 (en) | 2020-11-30 | 2021-05-07 | Dosing regimens associated with extended release paliperidone injectable formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025173295A Division JP2026027255A (ja) | 2020-11-30 | 2025-10-15 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023552329A JP2023552329A (ja) | 2023-12-15 |
| JP2023552329A5 true JP2023552329A5 (cg-RX-API-DMAC7.html) | 2024-05-17 |
| JP7792959B2 JP7792959B2 (ja) | 2025-12-26 |
Family
ID=75888043
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023532489A Active JP7792959B2 (ja) | 2020-11-30 | 2021-05-07 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
| JP2025173295A Pending JP2026027255A (ja) | 2020-11-30 | 2025-10-15 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025173295A Pending JP2026027255A (ja) | 2020-11-30 | 2025-10-15 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Country Status (22)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4025188B1 (en) * | 2020-11-30 | 2024-01-10 | Janssen Pharmaceutica NV | Dosing regimens associated with extended release paliperidone injectable formulations |
| PL4005555T3 (pl) | 2020-11-30 | 2024-09-02 | Janssen Pharmaceutica Nv | Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu |
| SI4025187T1 (sl) | 2020-11-30 | 2024-03-29 | Janssen Pharmaceutica Nv | Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem |
| CN116528836A (zh) | 2020-11-30 | 2023-08-01 | 詹森药业有限公司 | 与延长释放帕潘立酮可注射制剂相关的给药方案 |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| CN101163702B (zh) | 2005-04-25 | 2011-09-07 | 詹森药业有限公司 | 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法 |
| CA2655335C (en) * | 2007-12-19 | 2016-09-06 | Janssen Pharmaceutica N.V. | Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same |
| US8758780B2 (en) | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| AU2010313290A1 (en) * | 2009-10-30 | 2012-05-17 | Janssen Pharmaceutica Nv | Dosing regimen associated with long-acting injectable paliperidone esters |
| SI2529757T1 (sl) | 2011-05-31 | 2014-05-30 | Laboratorios Farmaceuticos Rovi, S.A. | Formulacija paliperidon implantata |
| WO2016157061A1 (en) * | 2015-03-31 | 2016-10-06 | Wockhardt Limited | Aseptic wet milling process for paliperidone palmitate |
| DK3744326T3 (da) * | 2015-04-07 | 2024-02-05 | Janssen Pharmaceutica Nv | Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere |
| CN114783258A (zh) | 2015-06-19 | 2022-07-22 | 詹森药业有限公司 | 用于药物施用和混合的系统及用于所述系统的适当技术的训练 |
| US20190183896A1 (en) * | 2017-12-14 | 2019-06-20 | SpecGx LLC | One step milling process for preparing micronized paliperidone esters |
| EP4025188B1 (en) * | 2020-11-30 | 2024-01-10 | Janssen Pharmaceutica NV | Dosing regimens associated with extended release paliperidone injectable formulations |
-
2021
- 2021-05-07 EP EP21724652.9A patent/EP4025188B1/en active Active
- 2021-05-07 DK DK21724652.9T patent/DK4025188T3/da active
- 2021-05-07 PL PL21724652.9T patent/PL4025188T3/pl unknown
- 2021-05-07 LT LTEPPCT/EP2021/062147T patent/LT4025188T/lt unknown
- 2021-05-07 TW TW110116515A patent/TWI877363B/zh active
- 2021-05-07 FI FIEP21724652.9T patent/FI4025188T3/fi active
- 2021-05-07 PT PT217246529T patent/PT4025188T/pt unknown
- 2021-05-07 IL IL303253A patent/IL303253A/en unknown
- 2021-05-07 HU HUE21724652A patent/HUE065573T2/hu unknown
- 2021-05-07 TW TW114105894A patent/TWI926646B/zh active
- 2021-05-07 SM SM20240077T patent/SMT202400077T1/it unknown
- 2021-05-07 KR KR1020257011387A patent/KR20250053980A/ko active Pending
- 2021-05-07 ES ES21724652T patent/ES2973583T3/es active Active
- 2021-05-07 JP JP2023532489A patent/JP7792959B2/ja active Active
- 2021-05-07 MX MX2023006366A patent/MX2023006366A/es unknown
- 2021-05-07 WO PCT/EP2021/062147 patent/WO2022111859A1/en not_active Ceased
- 2021-05-07 SI SI202130102T patent/SI4025188T1/sl unknown
- 2021-05-07 EP EP23219765.7A patent/EP4356966A3/en active Pending
- 2021-05-07 AU AU2021386450A patent/AU2021386450B2/en active Active
- 2021-05-07 CA CA3203566A patent/CA3203566A1/en active Pending
- 2021-05-07 US US17/314,330 patent/US11304951B1/en active Active
- 2021-05-07 CN CN202180080433.0A patent/CN116583270A/zh active Pending
- 2021-05-07 KR KR1020237021429A patent/KR102794804B1/ko active Active
- 2021-05-07 HR HRP20240074TT patent/HRP20240074T1/hr unknown
- 2021-05-07 RS RS20240116A patent/RS65178B1/sr unknown
-
2022
- 2022-04-13 US US17/719,686 patent/US20220249495A1/en not_active Abandoned
-
2023
- 2023-05-30 MX MX2024009188A patent/MX2024009188A/es unknown
-
2024
- 2024-06-20 AU AU2024204213A patent/AU2024204213B2/en active Active
-
2025
- 2025-08-06 US US19/291,832 patent/US20260060986A1/en active Pending
- 2025-10-15 JP JP2025173295A patent/JP2026027255A/ja active Pending
-
2026
- 2026-05-12 AU AU2026203613A patent/AU2026203613A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023552149A5 (cg-RX-API-DMAC7.html) | ||
| JP3701870B2 (ja) | 末梢血管疾患治療のための9−デオキシ−2’,9−α−メタノ−3−オキサ−4,5,6−トリノール−3,7−(1’,3’−インターフェニ | |
| JP2023551009A5 (cg-RX-API-DMAC7.html) | ||
| JP2022539821A5 (cg-RX-API-DMAC7.html) | ||
| JPH10511075A (ja) | 骨格筋収縮を阻害する酸化窒素種および付加物の使用 | |
| JP2023535744A5 (cg-RX-API-DMAC7.html) | ||
| FI4025188T3 (fi) | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia | |
| JP2022526763A5 (cg-RX-API-DMAC7.html) | ||
| AU618997B2 (en) | Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer | |
| FI4025189T3 (fi) | Viivästetysti vapauttavaan injektoitavaan paliperidoniin liittyviä annostusohjelmia | |
| FI4025187T3 (fi) | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia | |
| EP2116241B1 (en) | Pharmaceutical composition | |
| EA004474B1 (ru) | Комбинированное лечение заболевания цнс, особенно болезни паркинсона, путём совместного введения каберголина и прамипексола | |
| EP4144360A1 (en) | Sars-cov-2 antiviral drug antiprovir | |
| MX2021008208A (es) | Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. | |
| CN111166898B (zh) | 锝[99Tc]唑来膦酸在制备治疗骨质疏松药物中的应用 | |
| JP2023520703A5 (cg-RX-API-DMAC7.html) | ||
| TWI289060B (en) | Pharmaceutical composition for improving the recovery of post-stroke patients | |
| JP2022538898A5 (cg-RX-API-DMAC7.html) | ||
| KR20210137484A (ko) | 캡시드 조립 조절제 고체 제형 | |
| US11452710B1 (en) | Micronutrient and plant extract composition and method of improving bone health | |
| JP2627914B2 (ja) | プロスタグランジン類の選択的作用増強剤 | |
| US11364218B2 (en) | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome | |
| EP1518554B1 (en) | Pharmaceutical composition for the treatment of hyperhomocysteinemia | |
| JPH0213644B2 (cg-RX-API-DMAC7.html) |